Aardvark's (AARD) Registrational ph3 HERO RCT in PWS Remains On Track - Stifel
Tweet Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $24.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
